Brief: Jacobio Pharmaceuticals Got Investigational New Drug Approval From U.S. FDA
23/09/2024 24:42
Sept 23 (Reuters) - Jacobio Pharmaceuticals Group Co Ltd
1167.HK :
* GOT INVESTIGATIONAL NEW DRUG APPROVAL FROM U.S. FDA FOR
PAN-KRAS
INHIBITOR JAB-23E73
Further company coverage: 1167.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jacobio Pharmaceuticals
See all newsBrief: Jacobio Pharmaceuticals Appoints Xiaojie Wang As Vice Chairperson
China's Jacobio Pharmaceuticals H1 revenue jumps on licensing boost
Brief: Jacobio Pharmaceuticals Group Posts H1 Net Income Attributable RMB 600.6 Million
Brief: Jacobio Pharmaceuticals Expects HY Net Profit Of Not Less Than RMB600 Million
HK-listed Jacobio Pharmaceuticals climbs on share buyback plan